Northwest Bioth Cmn (NWBO): Price and Financial Metrics

NWBO POWR Grades

• Growth is the dimension where NWBO ranks best; there it ranks ahead of 77.62% of US stocks.
• NWBO's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
• NWBO's current lowest rank is in the Quality metric (where it is better than 10.79% of US stocks).

NWBO Stock Summary

• With a price/sales ratio of 370.96, NORTHWEST BIOTHERAPEUTICS INC has a higher such ratio than 98.83% of stocks in our set.
• Over the past twelve months, NWBO has reported earnings growth of -206.67%, putting it ahead of merely 6.31% of US stocks in our set.
• As for revenue growth, note that NWBO's revenue has grown 91.9% over the past 12 months; that beats the revenue growth of 95.13% of US companies in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to NORTHWEST BIOTHERAPEUTICS INC are FCEL, ASXC, LCTX, LGVN, and OMIC.
• NWBO's SEC filings can be seen here. And to visit NORTHWEST BIOTHERAPEUTICS INC's official web site, go to www.nwbio.com.

NWBO Valuation Summary

• In comparison to the median Healthcare stock, NWBO's price/sales ratio is 9140.48% higher, now standing at 388.1.
• Over the past 243 months, NWBO's price/sales ratio has gone up 379.6.

Below are key valuation metrics over time for NWBO.

NWBO Growth Metrics

The 2 year cash and equivalents growth rate now stands at 811.39%.
• The 5 year net income to common stockholders growth rate now stands at 103.65%.
• Its 4 year price growth rate is now at 137.5%.

Over the past 15 months, NWBO's revenue has gone down $288,000.

The table below shows NWBO's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	1.086	-55.172	56.586
2022-06-30	1.23	-46.067	134.957
2022-03-31	1.169	-38.018	169.035
2021-12-31	1.005	-38.299	179.126
2021-09-30	1.508	-37.256	-234.493
2021-06-30	1.374	-38.265	-474.108

NWBO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• NWBO has a Quality Grade of C, ranking ahead of 27.35% of graded US stocks.
• NWBO's asset turnover comes in at 0.045 -- ranking 328th of 682 Pharmaceutical Products stocks.
• EDSA, BLCM, and GLYC are the stocks whose asset turnover ratios are most correlated with NWBO.

The table below shows NWBO's key quality metrics over time.